Research programme: hormone therapies - Juniper Pharmaceuticals

Drug Profile

Research programme: hormone therapies - Juniper Pharmaceuticals

Alternative Names: Estrogen/progesterone intravaginal - Juniper Pharmaceuticals; JNP 0201; JNP 0301; Progesterone intravaginal - Juniper Pharmaceuticals

Latest Information Update: 02 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Juniper Pharmaceuticals
  • Class Gonadal steroid hormones; Hormonal replacements
  • Mechanism of Action Estrogen receptor modulators; Progesterone receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Menopausal syndrome; Preterm labour

Most Recent Events

  • 25 Apr 2018 JNP 0201 and JNP 0301 licensed to Dare Bioscience
  • 02 Jan 2018 Preclinical development is ongoing in Preterm-labour
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Preterm-labour in USA (Vaginal, Ring)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top